The Experts below are selected from a list of 75 Experts worldwide ranked by ideXlab platform
James C Pile - One of the best experts on this subject based on the ideXlab platform.
-
rhabdomyolysis after ingestion of foxy a hallucinogenic Tryptamine Derivative
Mayo Clinic Proceedings, 2006Co-Authors: Gheath Alatrash, Navneet S Majhail, James C PileAbstract:“Foxy methoxy” (chemical name, 5-methoxy-N,N-diisopropylTryptamine) is a hallucinogenic Tryptamine that has been abused with increasing frequency since its appearance in the late 1990s. Like other drugs in this class, foxy frequently produces feelings of euphoria, disinhibition, and auditory as well as visual hallucinations. The drug has been linked to adverse effects, including restlessness, agitation, gastrointestinal distress, and muscle tension. In light of the relatively recent advent of foxy as a drug of abuse and given the inability of commercial toxicologic screening tests to detect the presence of hallucinogenic Tryptamines, additional adverse effects seem probable. We report ingestion of foxy by a healthy 23-year-old man that resulted in rhabdomyolysis and transient acute renal failure.
-
Rhabdomyolysis After Ingestion of “Foxy,” a Hallucinogenic Tryptamine Derivative
Mayo Clinic Proceedings, 2006Co-Authors: Gheath Alatrash, Navneet S Majhail, James C PileAbstract:“Foxy methoxy” (chemical name, 5-methoxy-N,N-diisopropylTryptamine) is a hallucinogenic Tryptamine that has been abused with increasing frequency since its appearance in the late 1990s. Like other drugs in this class, foxy frequently produces feelings of euphoria, disinhibition, and auditory as well as visual hallucinations. The drug has been linked to adverse effects, including restlessness, agitation, gastrointestinal distress, and muscle tension. In light of the relatively recent advent of foxy as a drug of abuse and given the inability of commercial toxicologic screening tests to detect the presence of hallucinogenic Tryptamines, additional adverse effects seem probable. We report ingestion of foxy by a healthy 23-year-old man that resulted in rhabdomyolysis and transient acute renal failure.
Navneet S Majhail - One of the best experts on this subject based on the ideXlab platform.
-
rhabdomyolysis after ingestion of foxy a hallucinogenic Tryptamine Derivative
Mayo Clinic Proceedings, 2006Co-Authors: Gheath Alatrash, Navneet S Majhail, James C PileAbstract:“Foxy methoxy” (chemical name, 5-methoxy-N,N-diisopropylTryptamine) is a hallucinogenic Tryptamine that has been abused with increasing frequency since its appearance in the late 1990s. Like other drugs in this class, foxy frequently produces feelings of euphoria, disinhibition, and auditory as well as visual hallucinations. The drug has been linked to adverse effects, including restlessness, agitation, gastrointestinal distress, and muscle tension. In light of the relatively recent advent of foxy as a drug of abuse and given the inability of commercial toxicologic screening tests to detect the presence of hallucinogenic Tryptamines, additional adverse effects seem probable. We report ingestion of foxy by a healthy 23-year-old man that resulted in rhabdomyolysis and transient acute renal failure.
-
Rhabdomyolysis After Ingestion of “Foxy,” a Hallucinogenic Tryptamine Derivative
Mayo Clinic Proceedings, 2006Co-Authors: Gheath Alatrash, Navneet S Majhail, James C PileAbstract:“Foxy methoxy” (chemical name, 5-methoxy-N,N-diisopropylTryptamine) is a hallucinogenic Tryptamine that has been abused with increasing frequency since its appearance in the late 1990s. Like other drugs in this class, foxy frequently produces feelings of euphoria, disinhibition, and auditory as well as visual hallucinations. The drug has been linked to adverse effects, including restlessness, agitation, gastrointestinal distress, and muscle tension. In light of the relatively recent advent of foxy as a drug of abuse and given the inability of commercial toxicologic screening tests to detect the presence of hallucinogenic Tryptamines, additional adverse effects seem probable. We report ingestion of foxy by a healthy 23-year-old man that resulted in rhabdomyolysis and transient acute renal failure.
Hitoshi Tsuchihashi - One of the best experts on this subject based on the ideXlab platform.
-
metabolism of the psychotomimetic Tryptamine Derivative 5 methoxy n n diisopropylTryptamine in humans identification and quantification of its urinary metabolites
Drug Metabolism and Disposition, 2006Co-Authors: Tooru Kamata, Munehiro Katagi, Hiroe Kamata, Akihiro Miki, Noriaki Shima, Kei Zaitsu, Mayumi Nishikawa, Einosuke Tanaka, Katsuya Honda, Hitoshi TsuchihashiAbstract:The urinary metabolites of 5-methoxy-N,N-diisopropylTryptamine (5-MeO-DIPT) in humans have been investigated by analyzing urine specimens from its users. For the unequivocal identification and accurate quantification of its major metabolites, careful analyses were conducted by gas chromatography/mass spectrometry, liquid chromatography/mass spectrometry, and liquid chromatography-tandem mass spectrometry, using authentic standards of each metabolite synthesized. Three major metabolic pathways were revealed as follows: 1) side chain degradation by O-demethylation to form 5-hydroxy-N,N-diisopropylTryptamine (5-OH-DIPT), which would be partly conjugated to its sulfate and glucuronide; 2) direct hydroxylation on position 6 of the aromatic ring of 5-MeO-DIPT, and/or methylation of the hydroxyl group on position 5 after hydroxylation on position 6 of the aromatic ring of 5-OH-DIPT, to produce 6-hydroxy-5-methoxy-N,N-diisopropylTryptamine (6-OH-5-MeO-DIPT), followed by conjugation to its sulfate and glucuronide; and 3) side chain degradation by N-deisopropylation, to the corresponding secondary amine 5-methoxy-N-isopropylTryptamine (5-MeO-NIPT). Of these metabolites, which retain structural characteristics of the parent drug, 5-OH-DIPT and 6-OH-5-MeO-DIPT were found to be more abundant than 5-MeO-NIPT. Although the parent drug 5-MeO-DIPT was detectable even 35 h after dosing, no trace of its N-oxide was detected in any of the specimens examined.
Yoshikazu Mikami - One of the best experts on this subject based on the ideXlab platform.
-
ssh bm i a Tryptamine Derivative stimulates mineralization in terminal osteoblast differentiation but inhibits osteogenesis of pre committed progenitor cells
Journal of Pharmacological Sciences, 2011Co-Authors: Yoshikazu Mikami, M Somei, Hiromasa TsudaAbstract:Abstract. SSH-BM-I was synthesized from Tryptamine by using a newly developed synthetic method, and it has structural similarity to bromomelatonin. Recently, it had been reported that SSH-BM-I increases osteoblasts in scales of gold fish. However, the effect of SSH-BM-I on osteoblast differentiation in mammalian cells has not yet been examined. Therefore, this study examined the effect of SSH-BM-I on osteoblast differentiation in mesenchymal progenitor-like cells and mature osteoblast-like cells. SSH-BM-I enhanced terminal osteoblast differentiation, as indicated by mineralization, which was accompanied by upregulation of the osteogenic marker genes bone sialoprotein (BSP) and osteocalcin (OC). However, in mesenchymal progenitor ROB-C26 cultures, no mineralized nodules were observed regardless of SSH-BM-I treatment, although BMP-2 was able to induce nodule formation in these cells. Furthermore, BMP-2–induced nodule formation was suppressed by SSH-BM-I treatment in ROB-C26 cultures. We further investigated the impact of the timing and duration of SSH-BM-I treatment on osteoblast differentiation. The effect of SSH-BM-I treatment on osteoblast differentiation of ROB-C26 in the presence of BMP-2 switches from negative to positive sometime between day 6 and 9, because SSH-BM-I treatment enhanced the formation of mineralized nodules when it was started on day 9, but suppressed nodule formation when it was started at day 6 or earlier. These results suggest that the stimulatory effects of SSH-BM-I on the formation of mineralized nodules depend on the degree of cell differentiation.
-
inhibitory effects of a Tryptamine Derivative on ultraviolet radiation induced apoptosis in mc3t3 e1 mouse osteoblasts
Journal of Pharmacological Sciences, 2011Co-Authors: Yoshikazu Mikami, Motoki Senoo, Kiyoshi Yamada, Kuniyasu Ochiai, Masaki J Honda, Eri Watanabe, Nobukazu Watanabe, M Somei, Minoru TakagiAbstract:Abstract MS-IPA1 is a new synthetic compound that is synthesized from Tryptamine. Recently, our group demonstrated that SST-VED-I-1, which has a similar chemical structure to MS-IPA1, inhibits starvation-induced apoptosis in osteoblasts. However, the effects of MS-IPA1 on apoptosis in osteoblasts have not yet been examined. Therefore, this study examined the effects of this compound on apoptosis in osteoblasts. In this study, MC3T3-E1 mouse osteoblasts were used and apoptosis was induced by ultraviolet radiation (UV). We investigated the effect of MS-IPA1 on apoptosis by analyzing caspase3/7 activity, translocation of phosphatidylserine (PS), and mRNA expression levels of Bcl-2 and Bax. In addition, it was investigated whether MS-IPA1 affects cell proliferation and cell cycle progression. We found that MS-IPA1 had no effect on cell proliferation or cell cycle progression. However, MS-IPA1 suppressed UV-induced cell death in a dose-dependent manner, which was accompanied with the inhibition of caspase activation and translocation of PS. Furthermore, after UV exposure, Bcl-2 expression was increased in the MS-IPA1–treated cells as compared to that in the vehicle-treated cells. In contrast, Bax expression was decreased in the MS-IPA1–treated cell as compared to that in the vehicle-treated cells. These results suggest that MS-IPA1 has an inhibitory effect on apoptosis in osteoblasts through a Bcl-2 family-dependent signaling pathway.
-
a Tryptamine Derivative sst vedi 1 inhibits apoptosis and stimulates mineralization in osteoblasts
Endocrine Journal, 2009Co-Authors: Yoshikazu Mikami, Masanori Somei, Minoru TakagiAbstract:: SST-VEDI-1(VEDI-1) is a new synthetic compound that is synthesized from Tryptamine, and has structural similarity to the SSH-BM family of compounds. However, the biological effects of VEDI-1 have yet to be well characterized. A recent report has demonstrated that SSH-BM-type compounds can stimulate osteoblast activity in cultured scales of goldfish. In this study, we examined the effects of VEDI-1 on osteoblastic differentiation as well as its effects on apoptosis, which is known to be closely related to osteoblastic differentiation. We found that VEDI-1 enhanced the formation of mineralized nodules in rat osteoblast cell lines, including ROS17/2.8 cells, and in mouse pre-osteoblast cell lines, including MC3T3-E1 cells, in a dose dependent manner, which was accompanied by increased expression of late osteoblast markers, bone sialoprotein (BSP) and osteocalcin (OC). Furthermore, VEDI-I inhibited apoptotic cell death and regulated the expression of proteins in the Bcl-2 family. These results suggest that VEDI-1 may facilitate late differentiation of osteoblasts and may have an inhibitory effect on apoptosis.
Gheath Alatrash - One of the best experts on this subject based on the ideXlab platform.
-
rhabdomyolysis after ingestion of foxy a hallucinogenic Tryptamine Derivative
Mayo Clinic Proceedings, 2006Co-Authors: Gheath Alatrash, Navneet S Majhail, James C PileAbstract:“Foxy methoxy” (chemical name, 5-methoxy-N,N-diisopropylTryptamine) is a hallucinogenic Tryptamine that has been abused with increasing frequency since its appearance in the late 1990s. Like other drugs in this class, foxy frequently produces feelings of euphoria, disinhibition, and auditory as well as visual hallucinations. The drug has been linked to adverse effects, including restlessness, agitation, gastrointestinal distress, and muscle tension. In light of the relatively recent advent of foxy as a drug of abuse and given the inability of commercial toxicologic screening tests to detect the presence of hallucinogenic Tryptamines, additional adverse effects seem probable. We report ingestion of foxy by a healthy 23-year-old man that resulted in rhabdomyolysis and transient acute renal failure.
-
Rhabdomyolysis After Ingestion of “Foxy,” a Hallucinogenic Tryptamine Derivative
Mayo Clinic Proceedings, 2006Co-Authors: Gheath Alatrash, Navneet S Majhail, James C PileAbstract:“Foxy methoxy” (chemical name, 5-methoxy-N,N-diisopropylTryptamine) is a hallucinogenic Tryptamine that has been abused with increasing frequency since its appearance in the late 1990s. Like other drugs in this class, foxy frequently produces feelings of euphoria, disinhibition, and auditory as well as visual hallucinations. The drug has been linked to adverse effects, including restlessness, agitation, gastrointestinal distress, and muscle tension. In light of the relatively recent advent of foxy as a drug of abuse and given the inability of commercial toxicologic screening tests to detect the presence of hallucinogenic Tryptamines, additional adverse effects seem probable. We report ingestion of foxy by a healthy 23-year-old man that resulted in rhabdomyolysis and transient acute renal failure.
